Literature DB >> 31014138

Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1.

Ibrahim Aldoss1, Vinod Pullarkat1.   

Abstract

Entities:  

Year:  2019        PMID： 31014138     DOI： 10.1080/10428194.2019.1605510

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.

Authors:  Valentina Nardi; Steven L McAfee; Paola Dal Cin; Harrison K Tsai; Philip C Amrein; Gabriela S Hobbs; Andrew M Brunner; Rupa Narayan; Julia Foster; Amir T Fathi; Hanno Hock
Journal:  Oncologist       Date:  2022-03-04       Impact factor: 5.837

2.  Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion.

Authors:  Egle Stukaite-Ruibiene; Rimvydas Norvilas; Vaidas Dirse; Sigita Stankeviciene; Goda Elizabeta Vaitkeviciene
Journal:  Pathol Oncol Res       Date:  2022-09-12       Impact factor: 2.874

3.  Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing.

Authors:  Huan-Ping Wang; Jun-Jun He; Qiao-Yun Zhu; Lin Wang; Jian-Hu Li; Jian-Song Huang; Wan-Zhuo Xie; Hong-Hu Zhu; Jie Jin
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.